Individual risk profiling for breast cancer recurrence: towards tailored follow-up schemes

被引:14
作者
Kraeima, J. [1 ,2 ]
Siesling, S. [1 ,3 ]
Vliegen, I. M. H. [2 ]
Klaase, J. M. [4 ]
IJzerman, M. J. [1 ]
机构
[1] Univ Twente, Dept Hlth Technol & Serv Res HTSR, MIRA Inst Biomed Technol & Tech Med, NL-7500 AE Enschede, Netherlands
[2] CTIT, CHOIR, NL-7500 AE Enschede, Netherlands
[3] Comprehens Canc Ctr Netherlands IKNL, Dept Registrat & Res, NL-3511 GD Utrecht, Netherlands
[4] Med Spectrum Twente, Dept Surg, NL-7500 KA Enschede, Netherlands
关键词
breast cancer; follow-up; locoregional recurrence; prognostic factor; personalised medicine; CLINICAL-PRACTICE GUIDELINES; CONSERVING THERAPY; TUMOR RECURRENCE; EORTC; 10801; MASTECTOMY; IMPACT; MAMMOGRAPHY; VALIDATION; CARE;
D O I
10.1038/bjc.2013.401
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Breast cancer follow-up is not tailored to the risk of locoregional recurrences (LRRs) in individual patients or as a function of time. The objective of this study was to identify prognostic factors and to estimate individual and time-dependent LRR risk rates. Methods: Prognostic factors for LRR were identified by a scoping literature review, expert consultation, and stepwise multivariate regression analysis based on 5 years of data from women diagnosed with breast cancer in the Netherlands in 2005 or 2006 (n = 17 762). Inter-patient variability was elucidated by examples of 5-year risk profiles of average-, medium-, and high-risk patients, whereby 6-month interval risks were derived from regression estimates. Results: Eight prognostic factors were identified: age, tumour size, multifocality, gradation, adjuvant chemo-, adjuvant radiation-, hormonal therapy, and triple-negative receptor status. Risk profiles of the low-, average-, and high-risk example patients showed non-uniform distribution of recurrence risks (2.9, 7.6, and 9.2%, respectively, over a 5-year period). Conclusion: Individual risk profiles differ substantially in subgroups of patients defined by prognostic factors for recurrence and over time as defined in 6-month time intervals. To tailor follow-up schedules and to optimise allocation of scarce resources, risk factors, frequency, and duration of follow-up should be taken into account.
引用
收藏
页码:866 / 871
页数:6
相关论文
共 50 条
  • [41] Pattern of follow-up care and early relapse detection in breast cancer patients
    Geurts, Sandra M. E.
    de Vegt, Femmie
    Siesling, Sabine
    Flobbe, Karin
    Aben, Katja K. H.
    van der Heiden-van der Loo, Margriet
    Verbeek, Andre L. M.
    van Dijck, Jos A. A. M.
    Tjan-Heijnen, Vivianne C. G.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 859 - 868
  • [42] The reality in the follow-up of breast cancer survivors: survey of Korean Breast Cancer Society
    Kim, Ku Sang
    Kim, Zisun
    Shim, Eun-Jung
    Kim, Nam Hyoung
    Jung, So-Youn
    Kim, Jisun
    Sohn, Guiyun
    Lee, Jong Won
    Chos, Jihyoung
    Lee, Jung Eun
    Lee, Juhyung
    Youn, Hyun Jo
    Lee, Jihyoun
    Lee, Min Hyuk
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2015, 88 (03) : 133 - 139
  • [43] Disease recurrence and survival in patients with multifocal breast cancer: a follow-up study with 7-year results
    Kuan, Li Lian
    Tiong, Leong Ung
    Parkyn, Robert
    Walters, David
    Lai, Christine
    Walsh, David
    ANZ JOURNAL OF SURGERY, 2017, 87 (10) : E125 - E128
  • [44] From clinical symptoms to imaging in breast cancer follow-up
    Ceugnart, Luc
    Pasquier, David
    Jarraya, Hajer
    Rocourt, Nathalie
    Boulanger, Thomas
    Bercez, Herve
    Bachelle, Florence
    Chaveron, Celine
    Taieb, Sophie
    IMAGERIE DE LA FEMME, 2015, 25 (02) : 76 - 87
  • [45] Follow-up in Early Breast Cancer - A Surgical and Radiological Perceptive
    Dunn, J. A.
    Donnelly, P. K.
    Marshall, A.
    Wilcox, M.
    Watson, E.
    Young, A.
    Balmer, C.
    Ramirez, M.
    Hartup, S.
    Maxwell, A. J.
    Evans, A. J.
    CLINICAL ONCOLOGY, 2014, 26 (10) : 625 - 629
  • [46] Advantages and limitations of FDG PET in the follow-up of breast cancer
    Lind P.
    Igerc I.
    Beyer T.
    Reinprecht P.
    Hausegger K.
    European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 (SUPPL. 1) : S125 - S134
  • [47] PERCEPTIONS OF FOLLOW-UP CARE IN WOMEN WITH BREAST-CANCER
    MUSS, HB
    TELL, GS
    CASE, LD
    ROBERTSON, P
    ATWELL, BM
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (01): : 55 - 59
  • [48] CA 125 measurement in the follow-up of breast cancer patients
    Bohmer, C
    Jager, W
    Lang, N
    ANTICANCER RESEARCH, 1997, 17 (4B) : 3099 - 3100
  • [49] Advantages and limitations of FDG PET in the follow-up of breast cancer
    Lind, P
    Igerc, I
    Beyer, T
    Reinprecht, P
    Hausegger, K
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S125 - S134
  • [50] Patient evaluation of breast cancer follow-up: A Danish survey
    Ruban, Pernille Urup
    Wulff, Christian Nielsen
    Sperling, Cecilie Dyg
    Sandager, Mette
    Jensen, Anders Bonde
    PATIENT EDUCATION AND COUNSELING, 2018, 101 (01) : 99 - 104